-
Avacta Announces FDA Approval of its Investigational New Drug Application for AVA6000
AmericanPharmaceuticalReview
December 02, 2021
Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer? and pre|CISION? platforms, announced that the FDA has approved its Investigational New Drug...
-
US FDA approves Avacta Group’s IND application for AVA6000
Pharmaceutical-Business-Review
November 30, 2021
?The US Food and Drug Administration (FDA) has granted approval to Avacta Group’s Investigational New Drug (IND) application for AVA6000, a new form of doxorubicin.
-
Avacta Announces AffiDX(R) SARS-CoV-2 Antigen Lateral Flow Test Distribution Agreement
americanpharmaceuticalreview
June 23, 2021
Avacta Group plc announced that it has entered into a non-exclusive distribution agreement with Calibre Scientific Inc. for Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test for use in the UK and European Economic Area (EEA).
-
Avacta’s Rapid Antigen Test Confirmed to Detect SARS-CoV-2 New Variants
americanpharmaceuticalreview
March 16, 2021
Avacta has announced the AffiDX? SARS-CoV-2 rapid antigen lateral flow test detects the dominant new variants of the coronavirus, known as the B117, or ‘Kent’, variant, and the D614G variant, as well as the original strain.
-
Novel chemotherapeutic pro-drug approved for FIH trial in the UK
europeanpharmaceuticalreview
February 20, 2021
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug’s developers.
-
Gamma Biosciences Announces Strategic Licensing Agreement by Astrea Bioseparations for Advanced Application of Avacta Affimer? Reagent Technology
PharmaSources.com
December 21, 2020
MENLO PARK, California and CAMBRIDGE, United Kingdom, December 21, 2020 – Gamma Biosciences, a life sciences tools platform created by KKR, today announced a licensing.
-
Avacta Announces SARS-CoV-2 Rapid Antigen Test Update
americanpharmaceuticalreview
December 08, 2020
Avacta Group has announced progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with ...
-
Avacta to Launch SARS-CoV-2 ELISA Laboratory Test
americanpharmaceuticalreview
September 17, 2020
Avacta, the developer of Affimer? biotherapeutics and reagents, has announced it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
-
Avacta to Launch SARS-CoV-2 ELISA Lab Test
contractpharma
September 17, 2020
To make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus.
-
Avacta Appoints Chief Development Officer
contractpharma
August 12, 2020
Neil Bell brings 30 years’ experience in the drug development industry.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
